| Identification | Back Directory | [Name]
AUNP-12 | [CAS]
1353563-85-5 | [Synonyms]
AUNP-12
AUR 012
Aurigene-012
Aurigene NP-12
AURIGENE-012;AUR 012
L-α-Glutamine, N2,N6-bis(L-seryl-L-asparaginyl-L-threonyl-L-seryl-L-α-glutamyl-L-seryl-L-phenylalanyl)-L-lysyl-L-phenylalanyl-L-arginyl-L-valyl-L-threonyl-L-glutaminyl-L-leucyl-L-alanyl-L-prolyl-L-lysyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-lysyl- | [Molecular Formula]
C142H226N40O48 | [MDL Number]
MFCD01779848 | [MOL File]
1353563-85-5.mol | [Molecular Weight]
3261.55 |
| Chemical Properties | Back Directory | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Water: Soluble | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1]. | [Biological Activity]
AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a novel immune checkpoint modulator, is an inhibitor of PD-1 signaling pathway. | [in vitro]
In hPDL2-expressing HEK293 cells, AUNP-12 inhibited the binding of PD1 to PDL2 with EC50 of 0.72 nM; in hPDL1-expressing MDA-MB231 cells, in PBMC proliferation assay, EC50 was 0.41 nM. | [target]
| Target | Value | PD-L1
(Cell-free assay) |
| [References]
[1] Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. DOI:10.1158/1535-7163.MCT-18-0737 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|